William Lis has sold stock and made no open-market buys since May 2016

William Lis is a Person and serves as an independent director on the Board of Zai Lab Ltd.; he joined the board in October 2018 and is a member of the Audit Committee and Commercial Committee.( In June 2026, he reported an insider sale of 7,040 Zai Lab ADS in a Rule 10b5-1 transaction, following a prior equity grant in which he received 22,371 ADS.(

Lis has more than 30 years of biopharmaceutical industry experience across executive and board roles.( He is currently Executive Chairman of Tr1x Bio, Inc., and previously served as Executive Chairman and Interim CEO of Jasper Therapeutics, CEO and a director of Portola Pharmaceuticals, and in senior leadership roles at Scios/Johnson & Johnson and earlier at Millennium Pharmaceuticals, COR Therapeutics, and Rhône-Poulenc Rorer/Aventis, contributing to products including Xarelto®, Integrilin®, Lovenox®, Rilutek®, Velcade®, Andexxa®, and Bevyxxa®.( He holds a B.S. from the University of Maryland.(

Written by Perplexity from public sources.